Cancer name Kidney Renal Clear Cell Carcinoma
Cancer Type KIRC
Immunotherapy type Immune Checkpoint Therapy
Treatment Atezolizumab
Drugstatus Approved
Drugbank ID DB11595
Checkpoints PD-1
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action PROT_NR_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trail
Description Subgroup analyses for PFS and OS indicated a trend toward lower antitumor activity in patients with low-to-no PD-L1expression (IC0) compared with patients who expressed PD-L1(IC1/2/3).
PMID 26755520
Title Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.